ReviewAnnual review of vision science2024
Informing Endpoints for Clinical Trials of Geographic Atrophy.
Review in Annual review of vision science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Understanding the Geographic Atrophy Journey: Patient and Physician Perspectives to Inform Better Care.Ophthalmology and therapy · 2026Review
- Intereye Correlation in Bilateral Geographic Atrophy: Morphology and Growth Rates in the Age-Related Eye Disease Study.Ophthalmology science · 2026Article
- A Novel Pixel-Based Spatial Modeling Framework for Mapping At-Risk Retina in Geographic Atrophy Progression.Ophthalmology science · 2026Article
- Photoreceptor Density-Dependent Kinetics of Geographic Atrophy Progression.Ophthalmology science · 2026Article
- Complement Inhibition in Geographic Atrophy: Clinical Evidence for Pegcetacoplan and Avacincaptad Pegol.Cureus · 2026Review
- Association between Baseline Subfoveal Choroidal Thickness and Anatomical and Functional Outcomes in Geographic Atrophy.Ophthalmology science · 2026Article
- Structure-Function Correlation Using a Targeted Image-Guided Microperimetry Approach for Retinal Atrophic Diseases: A Methods Study.Translational vision science & technology · 2025Article
- Imaging of Geographic Atrophy: A Practical Approach.Ophthalmology and therapy · 2025Article
- Relationships Between Diet and Geographic Atrophy Progression in the Age-Related Eye Diseases Studies 1 and 2.Nutrients · 2025Article
- Age-related macular degeneration: natural history revisited in geographic atrophy.Eye (London, England) · 2025Review
- Article
- Geographic atrophy: Understanding the relationship between structure and function.Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Geographic atrophy (GA), the non-neovascular advanced form of age-related macular degeneration, remains an important disease area in which treatment needs are currently unmet. Recent clinical trials using drugs that target the complement pathway have shown modest yet consistent reductions in GA expansion but without commensurate changes in measures of visual function. In this review, we summarize information from the wide range of studies describing the characteristics of GA morphology and enumerate the factors influencing the growth rates of lesions and the directionality of expansion. In addition, we review the relationship between GA growth and the various measures of vision that reflect changes in function. We consider the reasons for the discordance between the anatomical and functional endpoints in current use and discuss methods to align these key outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.